Golden R N, Ekstrom D, Brown T M, Ruegg R, Evans D L, Haggerty J J, Garbutt J C, Pedersen C A, Mason G A, Browne J
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill 27599-7160.
Am J Psychiatry. 1992 Sep;149(9):1168-75. doi: 10.1176/ajp.149.9.1168.
Neuroendocrine challenge paradigms have been used to asses serotonergic systems in depression, but limitations in the specificity of many of these tests have been noted. In this study, the neuroendocrine responses to acute intravenous administration of the serotonin (5-HT) reuptake inhibitor clomipramine were assessed in depressed patients and matched control subjects.
Thirty hospitalized patients who met DSM-III-R criteria for major depression, and 30 healthy control subjects who were matched for age, sex, and season of year for the time of study, received 12.5 mg of intravenously administered clomipramine.
The depressed patients demonstrated significant blunting of prolactin responses to clomipramine, as well as trends toward blunted ACTH and cortisol responses. There was no difference between the patient and control groups in growth hormone responses, plasma clomipramine levels, or self-reports of side effects.
These data support the hypothesis that depressed patients have abnormal neuroendocrine responses to the intravenous administration of the 5-HT reuptake inhibitor clomipramine. Further study is required to delineate the mechanisms responsible for the abnormal response to intravenously administered clomipramine in depression.
神经内分泌激发范式已被用于评估抑郁症中的血清素能系统，但已注意到其中许多测试在特异性方面存在局限性。在本研究中，评估了抑郁症患者和匹配的对照受试者对静脉内急性给予血清素（5-羟色胺，5-HT）再摄取抑制剂氯米帕明的神经内分泌反应。
30名符合DSM-III-R重度抑郁症标准的住院患者以及30名在年龄、性别和研究时间的季节方面相匹配的健康对照受试者接受了12.5毫克静脉注射氯米帕明。
抑郁症患者对氯米帕明的催乳素反应显著减弱，促肾上腺皮质激素（ACTH）和皮质醇反应也有减弱趋势。患者组和对照组在生长激素反应、血浆氯米帕明水平或副作用自我报告方面没有差异。
这些数据支持以下假设，即抑郁症患者对静脉注射5-HT再摄取抑制剂氯米帕明有异常神经内分泌反应。需要进一步研究来阐明抑郁症患者对静脉注射氯米帕明异常反应的机制。
